Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.26
- Piotroski Score 3.00
- Grade Outperform
- Symbol (ANIK)
- Company Anika Therapeutics, Inc.
- Price $16.99
- Changes Percentage (-2.52%)
- Change -$0.44
- Day Low $16.95
- Day High $17.62
- Year High $29.12
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$5.24
- Trailing P/E Ratio -4.92
- Forward P/E Ratio -4.92
- P/E Growth -4.92
- Net Income $-82,667,000
Income Statement
Quarterly
Annual
Latest News of ANIK
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Japanese poet Shuntaro Tanikawa, master of modern free verse, has died at 92
Renowned Japanese poet Shuntaro Tanikawa, known for his innovative and conversational style, has passed away at 92. His works, including "Two Billion Light Years of Solitude," resonated globally....
By AP NEWS | 5 days ago -
Who could run to replace Stefanik in the House?
Rep. Elise Stefanik, R-N.Y., is set to become U.S. ambassador to the United Nations, triggering a special election for her House seat. Potential contenders are being considered, including state Sen. D...
By Fox News | 1 week ago -
Trump's choice of Elise Stefanik for UN envoy offers hope for US...
Donald Trump's choice of Rep. Elise Stefanik as US ambassador to the United Nations is praised for her experience in Congress and strong stance against antisemitism. With her background in armed servi...
By New York Post | 1 week ago
